The guideline advances a new approach to risk assessment through a novel risk score, sets lower low-density lipoprotein cholesterol (LDL-C) and nonhigh-density lipoprotein cholesterol (HDL-C) treatment goals for patients with established atherosclerotic cardiovascular disease (ASCVD), and recommends measuring lipoprotein(a) [Lp(a)] at least once to identify individuals at higher risk of ASCVD.The guideline dissemination tools include a Central Illustration to graphically convey key concepts, as well as tables highlighting updates in the ACC/AHA/Multisociety Dyslipidemia Guideline and comparisons to the 2025 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) Focused Update of the 2019 Guidelines for the Management of Dyslipidaemias
For patients with clinically low testosterone, hormone optimization through TRT can further improve the ratio of fat lost to muscle preserved
In vitro and in vivo tumoricidal properties of a pathogenic/free-living amoeba
NAD + metabolism in physiological function Serving as crucial co-enzymes for redox reactions and co-substrates for NAD + -dependent enzymes, NAD + and its metabolites function as a regulatory hub controlling a broad range of physiological processes, including redox homeostasis, genomic stability, gene expression, RNA processing, energy metabolism, immunity and inflammation, and circadian clock
Rao 2007)
